CAPRISA - Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Private Bag X7, Congella, Durban 4013, South Africa.
Best Pract Res Clin Obstet Gynaecol. 2012 Aug;26(4):495-501. doi: 10.1016/j.bpobgyn.2012.02.004. Epub 2012 Apr 11.
The magnitude of the global human immunodeficiency virus (HIV) epidemic is determined by women from lower income countries, specifically sub-Saharan Africa. Microbicides offer women who are unable to negotiate safe sex practices a self-initiated HIV prevention method. Of note, is its potential to yield significant public health benefits even with relatively conservative efficacy, coverage and user adherence estimates, making microbicides an effective intervention to invest scarce healthcare resources. Existing healthcare delivery systems provide an excellent opportunity to identify women at highest risk for infection and to also provide an access point to initiate microbicide use. Innovative quality improvement approaches, which strengthen existing sexual reproductive health services and include HIV testing, and linkages to care and treatment services, provide an opportunity to lay the foundations for wide-scale provision of microbicides. The potential to enhance health outcomes in women and infants and potentially affect rates of new HIV infection may soon be realised.
全球人类免疫缺陷病毒 (HIV) 流行的规模由来自低收入国家的女性决定,特别是撒哈拉以南非洲地区的女性。杀微生物剂为那些无法协商安全性行为的女性提供了一种自我启动的 HIV 预防方法。值得注意的是,即使在相对保守的疗效、覆盖率和使用者依从性估计下,它也有可能带来重大的公共卫生效益,这使得杀微生物剂成为一种有效的干预措施,可以投入稀缺的医疗保健资源。现有的医疗保健提供系统为确定感染风险最高的女性提供了极好的机会,也为启动杀微生物剂的使用提供了一个切入点。创新的质量改进方法加强了现有的性生殖健康服务,包括 HIV 检测,并与护理和治疗服务建立联系,为大规模提供杀微生物剂奠定了基础。提高妇女和婴儿健康结果的潜力,并可能影响新的 HIV 感染率,可能很快就会实现。